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Abstract
Systemic corticosteroid use to manage uncontrolled asthma and its
associated healthcare burden may account for important health-
related adverse effects. We conducted a systematic literature review
to investigate the real-world extent and burden of systemic
corticosteroid use in asthma. We searched MEDLINE and Embase
databases to identify English-language articles published in
2010–2017, using search terms for asthma with keywords for oral
corticosteroids and systemic corticosteroids. Observational studies,
prescription database analyses, economic analyses, and surveys on
oral/systemic corticosteroid use in children (.5 yr old), adolescents
(12–17 yr old), and adults with asthma were included. We identiﬁed
and reviewed 387 full-text articles, and our review included data from
139 studies. The included studies were conducted in Europe, North
America, and Asia. Overall, oral/systemic corticosteroids were
commonly used for asthma management and were more frequently
used in patients with severe asthma than in those withmilder disease.
Long-term oral/systemic corticosteroid use was, in general, less
frequent than short-term use. Compared with no use, long-term and
repeated short-term oral/systemic corticosteroid use were associated
with an increased risk of acute and chronic adverse events, even
when doses were comparatively low. Greater oral/systemic
corticosteroid exposure was also associated with increased costs and
healthcare resource use. This review provides a comprehensive
overview of oral/systemic corticosteroid use and associated adverse
events for patients with all degrees of asthma severity and exposure
duration. We report that oral/systemic corticosteroid use is
prevalent in asthma management, and the risks of acute and chronic
complications increase with the cumulative oral corticosteroid
dosage.
Keywords: asthma; oral corticosteroids; severe asthma; systematic
literature review; systemic corticosteroids
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Systemic corticosteroids (SCS) became
available in 1956, and their introduction
provided effective treatment for the control
of asthma symptoms and exacerbations (1).
However, their widespread use quickly led
to the recognition that long-term SCS use is
associated with signiﬁcant adverse events
(AEs) (2). Inhaled CS (ICS), which have a
reduced risk of AEs but are as effective as
SCS for most patients, were introduced in
1972 as maintenance treatment for patients
with asthma (1, 3). However, SCS, usually
in the form of oral CS (OCS) and
occasionally as injectable CS, remained
the mainstay treatment for asthma
exacerbations and severe disease over the
next four decades (1, 4).
Today, ICS are the primary therapeutic
intervention for persistent asthma along with
other controller therapies, including
predominantly long-acting b2-agonists
(LABAs) and leukotriene receptor
antagonists, as additional treatments to
reduce ICS dosages, control asthma
symptoms, and decrease exacerbation risk
for patients with asthma (5). Add-on
treatments, traditionally long-acting
muscarinic antagonists or low-dosage OCS
(before the introduction of targeted
biologics), are recommended for patients
with asthma that is not controlled by
medium- to high-dosage ICS plus controller
medications (5). In 2003, omalizumab (anti-
IgE therapy), the ﬁrst targeted biologic
therapy for asthma, was approved by the
U.S. Food and Drug Administration for add-
on maintenance treatment (6). Subsequently,
the anti–IL-5 treatments mepolizumab and
reslizumab and the anti–IL-5 receptor
a–directed cytolytic therapy benralizumab
were approved for the treatment of severe,
eosinophilic asthma (6, 7). More recently,
the anti–IL-4 and anti–IL-13 therapy
dupilumab was approved for the treatment
of moderate-to-severe eosinophilic or OCS-
dependent asthma (8). These targeted
biologic treatments have demonstrated
greater speciﬁcity for achieving disease
control by reducing the risk of exacerbations
and requirements for rescue medication and
OCS use in their respective target patient
populations, with limited AEs (7–17).
Biologics are now also recommended in
guidelines for the treatment of appropriate
patients with severe asthma (5). For patients
with severe asthma who are not eligible for
the currently available biologic treatments,
the 2019 Global Initiative for Asthma
(GINA) guidelines recommend that several
other strategies be considered before
maintenance OCS/SCS (5).
Despite the availability of these new
well-tolerated, effective, targeted biologic
add-on treatments and the well-recognized
AEs associated with SCS use, OCS are still
treatment options in the current asthma
treatment guidelines. The 2019 GINA
guidelines recommend that if OCS are
prescribed, they should be prescribed at
lesser dosages. Prescribers should be fully
aware of and monitor for AEs. OCS should
be considered, along with targeted biologic
treatments, for add-on treatment for
patients with uncontrolled asthma despite
the use of high-dosage ICS therapy (GINA
step 5 treatment) (5). The GINA guidelines
also recommend short-term OCS use for
patients experiencing a severe exacerbation
who do not respond to treatment (5).
However, this guidance is relatively
unspeciﬁc. Patients can repeatedly receive
prescriptions for both short- and long-term
OCS and ultimately become OCS
dependent (18). The continued inclusion of
OCS in guidelines, together with their
worldwide easy accessibility, familiarity of
use, and low acquisition costs compared
with newer targeted treatments, contributes
to the ongoing use of SCS for patients with
severe asthma. In addition, it is likely that
some patients fail to beneﬁt signiﬁcantly
from the OCS-sparing effect of biologic
treatments because of differences in their
susceptibility to OCS-related adverse effects,
or because of their unwillingness to initiate
new treatment options and reduce OCS use.
Studies from France and the United
Kingdom provide evidence that overall OCS
use has increased over the last decade and
continues to increase (19, 20). Respiratory
disease is the most frequently recorded
indication for OCS treatment, accounting
for approximately 40% of prescriptions (20,
21). OCS use has declined in recent decades
for other indications for which biologics
have been available for more than 20 years.
In rheumatology, for example, the
introduction of biologics has signiﬁcantly
reduced OCS use, and this change has been
cost-effective in the treatment of
rheumatoid arthritis (22, 23).
Responses to SCS and the risk of AEs
vary considerably among patients (24).
Many patients with persistent SCS use
demonstrate a relative resistance to
treatment (24), but they continue to receive
SCS prescriptions and increasing dosages,
which further contributes to the prevalence
of long-term use. In recent studies in which
responses to SCS were comprehensively
characterized, 25–35% of patients with
asthma did not respond to OCS treatment
by exhibiting evidence of a reduction
in type 2 biomarkers, suggesting SCS
resistance (25, 26). However, despite these
ﬁndings and the extensive variation in
prescription durations and dosages used in
clinical practice, the optimal duration and
dosage of SCS maintenance and short-term
treatment have not been studied extensively
(27). A recent systematic literature review
evaluated the long-term use of OCS for
patients with asthma and reported that
the risk of developing OCS-related
complications, including infections,
diabetes, osteoporosis, and psychiatric
disorders, was greater for patients with
long-term OCS exposure compared with
control groups, even for those receiving
dosages below 5 mg/d (28). However, these
ﬁndings were limited to adult patients with
severe asthma and long-term OCS use and
were based on just nine publications (seven
large datasets).
In this systematic literature review, we
investigated the extent and nature of real-
world SCS use (oral and parenteral CS) for
the treatment of asthma in children (.5 yr
old), adolescents (12–17 yr old), and adults
with asthma of any severity. We also
examined available evidence regarding the
clinical and economic impacts of sporadic,
repeated short- and long-term SCS use in
the general asthma population and by the
degree of asthma severity. The ﬁndings
of this review provide a comprehensive
overview to improve our understanding of
the risk of health-related adverse effects
associated with SCS use for patients with
asthma and the extent of SCS use for
patients with all degrees of asthma severity.
Methods
Search Strategy and Selection
Criteria
A literature search was conducted in
MEDLINE and Embase databases via Ovid
to identify English-language articles
published between January 1, 2007, and
December 4, 2017, using the following
search terms: asthma AND ([corticosteroid
OR corticosteroids OR glucocorticoid OR
glucocorticoids OR prednisone OR
prednisolone OR dexamethasone OR
methylprednisolone OR hydrocortisone]
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AND [oral OR orally OR systemic OR
parenteral OR intravenous OR
intramuscular]) OR [SCS OR OCS]). Filters
were applied to exclude reviews, letters, and
information presented at scientiﬁc
conferences. Full search details are provided
in Table E1 in the online supplement.
Searches were initially restricted to English-
language articles published since 2007.
However, because of the large number of
relevant articles identiﬁed, and to ensure
that the most up-to-date data relevant to
current clinical practices were evaluated, the
search was subsequently limited to articles
published since January 1, 2010.
Abstracts and full-text articles were
screened to determine their eligibility for
inclusion according to prespeciﬁed patient-,
intervention-, comparison-, outcome-, and
study-design–related selection criteria
(Table 1). To summarize, the systematic
literature review included observational
studies that reported information on
frequency of SCS use and treatment
patterns, as well as clinical complications
and the economic burden associated with
SCS use for children (.5 yr old),
adolescents (12–17 yr old), and adults with
asthma of any degree of severity. Studies
that included ,100 patients with asthma
were excluded, as this sample size was
considered too small to provide results
likely to be representative of the overall
asthma population.
Data Analysis
Data from the included articles were
extracted into aMicrosoft Excel spreadsheet.
At extraction, studies were separated into
the following categories of use: oral (OCS),
parenteral, and systemic (both oral and
parenteral; SCS). The evidence identiﬁed
was summarized qualitatively, and studies
were separated according to whether they
reported long- or short-term use.
Results
Manuscript Identiﬁcation
The search identiﬁed 2,277 unique
references across the databases. Abstract
screening identiﬁed 387 references that
required further review of full-text articles.
Of those, 149 publications met the criteria
for inclusion (Figure 1). During data
extraction, related publications reporting
on the same patient populations or updates
from the same studies were identiﬁed. To
avoid study duplication, data from these
publications were only included once in the
analysis, resulting in 139 studies included in
the ﬁnal analyses. The most common
reason for exclusion at the full-text level
was no relevant data.
Study Populations
The included studies were conducted in
Europe, North America, and Asia (Table
E2). However, 64% of the studies presented
data from centers or databases in the United
States (n= 55) or the United Kingdom
(n= 34). UK studies accounted for 52%
(n= 34/65) of all studies from Europe.
Studies reporting data for adults
(n= 48/139) or combined adult/adolescent
populations (n= 44/139) accounted for
approximately two-thirds of the studies
(Table E2). Seventeen studies reported data
for individuals >5 years of age. Age limits
were undeﬁned in 14 studies, but mean or
median ages of >40 years were reported,
suggesting that the studies consisted of
largely adult populations.
Overall, 41% (n=57) of the studies
involved patients with any degree of disease
severity; 23% (n= 32) included data for
patients with GINA step 2 or greater
treatment, and 19% (n=26) involved only
patients with severe asthma (GINA step 4 or
5). Studies of patients with severe asthma
were smaller in size than those that covered
a wider degree of disease severity, with 22 of
26 studies including fewer than 1,000
patients. The majority of studies reported
data for OCS use (87%; n=121), although
some institutions, including centers
participating in the Severe Asthma Research
Program, exclusively recommended SCS use.
However, because the results reported for
SCS use were similar to those reported for
OCS use, the rest of this review will focus on
OCS use. The results for SCS use are
reported in the relevant corresponding tables
and online supplement.
Patterns of CS Use
Patterns of short-term CS use. Short-term
use was deﬁned by terms such as “acute,”
“burst,” and “for asthma exacerbations,” or
when OCS/SCS were used as reliever
medications or had a deﬁned short-term
exposure. Overall, 58 studies reported
short-term OCS/SCS use for patients with
asthma (Table E3). Short-term OCS/SCS
use in studies of patients with any degree of
asthma severity ranged from 3.6%
(underweight patients before OCS/SCS
exposure in a U.S. study of children with
asthma living in the vicinity of wildﬁres)
(29) to 62.0% (U.S. observational study of
primary care patients with asthma) (30).
Short-term OCS/SCS use in studies of
patients receiving GINA step 2 or greater
treatment ranged from 2.1% (international
study of SCS use for patients with asthma
>12 yr old) (31) to 41.9% (ﬂuticasone
propionate/salmeterol ﬁxed-dose
combination inhaler use in a U.S.
retrospective study) (32). Short-term
OCS/SCS use in studies of patients with
severe or difﬁcult-to-treat asthma ranged
from 23.2% (patients who experienced
exacerbations within the prior 3 mo in a U.S.
study of severe refractory asthma) (33) to
92.6% (UK study of OCS use for patients
with severe asthma [age unspeciﬁed]) (34).
The percentage of patients receiving short-
term OCS/SCS therapy increased with
increasing disease severity.
Patterns of short-term CS use by disease
severity. Five retrospective cohort studies of
adult patients with asthma of any degree of
severity reported that approximately a
quarter of patients required at least one
short-term OCS course during a 1-year
period (29, 35–38). Studies involving
patients of all ages reported incidences of
16.2–30.9% for 1-year use of short-term
OCS (39–41).
For patients with severe or difﬁcult-to-
treat asthma, short-term OCS use increased
to 46.3–92.6% over a 1-year period (33, 34,
42–46). In one cross-sectional study of
patients with uncontrolled asthma, 60% of
whom had severe asthma, 24.4% overall
were reported to have received greater than
or equal to 3 short-term OCS courses in the
previous year (42).
Short-term CS prescription use. The
mean number of OCS short-term
prescriptions ranged from 0.1 to 2.16
prescriptions per year in the nine studies
that reported these data for patients with
any degree of asthma severity or those using
controller therapy (GINA step 2 or greater
treatment) (32, 47–54). Studies involving
patients with severe or uncontrolled asthma
reported greater prescription rates compared
with patients with less severe disease. A study
that examined prescription rates in relation to
treatment steps (according to the British
Thoracic Society guidelines) reported that the
mean number of OCS courses per year
ranged from 1.2 to 2.1 at steps 1–4 and 5.3 at
step 5 (maintenance OCS therapy) (47).
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Patterns of long-term CS use. A total
of 62 studies evaluated long-term OCS
(54 studies) and SCS (eight studies) use
for patients with asthma, deﬁned as
“daily” or “continuous” OCS/SCS use, or
described OCS/SCS use as “chronic,”
“maintenance,” or “controller medication,”
or speciﬁed durations of long-term
OCS/SCS exposure. For patients with any
degree of asthma severity, long-term
OCS/SCS use ranged from 1.2% (UK
retrospective study of asthma therapy) (47)
to 30.9% (patients with asthma and vitamin
D insufﬁciency in a German study) (55)
(Table 2 [extended version: Table E4]). For
Table 1. Study Selection Criteria for the Systematic Literature Review on the Use of OCS and SCS for Treatment of Asthma
Category Inclusion Criteria Exclusion Criteria
Population d Pediatric, adolescent, and adult patients (>5 yr old) with
asthma of any severity and all degrees of disease control
d Mixed study populations or subpopulations in which
>85% of patients met the above criteria (apart from age
criteria, which had to be met by all patients)
d Children ,5 yr old with asthma
d Patients who did not have asthma
d Patients with ACOS
d Patients with asthma during pregnancy
d Mixed-study populations or subpopulations in
which ,85% of patients met the inclusion criteria
d Studies containing ,100 patients with asthma
d Studies containing ,500 patients with asthma,
except for those reporting long-term OCS/SCS
use or burden of OCS/SCS use
Intervention/
comparators
d OCS, parenteral CS, or SCS d No mention of OCS, parenteral CS, or SCS use
d CS treatment in emergency department and/or in
hospitalized patients with asthma only
Outcomes d Frequency/patterns of OCS and SCS use (patient-level
data)
d Long-term OCS and SCS use, including
Length of time (average duration) receiving long-term OCS
Dosage and frequency of changing dosage
d Outcome measures not listed in the inclusion
criteria
d Frequency/patterns of OCS and SCS use among
physicians
d Clinical burden of OCS and SCS use:
Asthma clinical features
Exacerbation history
Previous hospitalizations
Degree of asthma control (based on ACQ or ACT)
Phenotypes (eosinophilic, allergic, etc.)
Comorbidities and complications for OCS and SCS users:
Diabetes/metabolic
Bone (e.g., osteoporosis)
Cardiovascular disease
Psychiatric (e.g., depression)
Others as available
d Economic burden of OCS and SCS use:
Healthcare resource use, including hospitalizations
and doctor and emergency department visits
Costs (including direct and indirect costs), both
asthma-related and all costs
Cost consequences of prolonged OCS and SCS use
Study design d Observational studies, including prospective and
retrospective cohort studies, and cross-sectional analyses
d Prescription database analyses
d Economic analyses
d Patient, parent/guardian, and HCP surveys
d Systematic and narrative reviews
d Case reports and case series
d Comments, letters, and editorials
d Animal/in vitro studies
d Meta-analyses/pooled analyses
d Clinical trials
d Asthma phenotyping analyses
d Treatment guidelines
d Patient education studies
d Studies of healthcare management (e.g., physician
prescribing preferences, physician/hospital
management approaches, and care quality
evaluation)
Time period d January 1, 2007, to December 4, 2017 d Studies published before January 1, 2007, or after
December 4, 2017
Other criteria d Studies published in English
d Limited to humans
d Non–English language publications
d Conference abstracts
Definition of abbreviations: ACOS=asthma–chronic obstructive pulmonary disease overlap syndrome; ACQ=Asthma Control Questionnaire;
ACT=Asthma Control Test; HCP=healthcare professional; OCS=oral corticosteroids; SCS= systemic corticosteroids.
STATE OF THE ART
State of the Art 279
 
patients receiving GINA step 2 or
greater treatment, long-term OCS/SCS
use ranged from 0% (patients with
nonsevere asthma in a U.S. study)
to 100% (UK study of patients with
severe asthma) (54). In general, long-term
OCS/SCS use was less frequent than
short-term use.
Patterns of long-term CS use by disease
severity. In general, ,12% of patients
with any degree of asthma severity received
long-term OCS therapy (although values
varied from 0.5% to 26.8% in different
studies) (35, 55). This degree of variation
could partly be related to how the studies
deﬁned long-term use, as well as differences
in study inclusion criteria, geographic
region, and availability of OCS-sparing
treatments. Rates in 11 studies that applied
precise deﬁnitions ranged from 0.5% to
9.4%, with ﬁve studies reporting rates of
,3% (35, 47, 56–58). Studies that used
more generalized terms, such as “regular
OCS” and “controller medication,”
reported rates of 4–20.5% (59–66).
Long-term OCS use was consistently
reported as low across all age groups for
patients with nonsevere disease (1.3% and
0.0% of children/adolescents and adults,
respectively) (25). Among patients with
severe or uncontrolled asthma, 20–60%
were reported to have received long-term
OCS therapy.
Long-term CS dosage. The dosage of
long-term OCS was reported in 23 studies,
most of which reported results for patients
with severe disease. The mean daily OCS
dosage (expressed as prednisolone-
equivalent dosages) ranged from 4.0 to
21.4 mg (Table E5) (67, 68). In 12 of these
studies, the mean daily dosage was
10–22 mg (34, 43, 55, 68–76).
Patterns of general CS use. Studies that
did not specify short- or long-term use were
classiﬁed as reporting general OCS use.
These were studies that described any
OCS/SCS use, or those in which OCS/SCS
use was undeﬁned and/or described with
general terms, such as “OCS prescriptions,”
“OCS use,” and “OCS claims.”
General CS use by disease
severity. Forty-one studies reported general
SCS/OCS use. Overall, OCS/SCS were
reported to be commonly used for asthma
management (Table 3 [extended version:
Table E6]). Use was more frequent for
patients with severe asthma than for those
with milder disease. Reported OCS/SCS use
varied considerably across a variety of
patient populations, ranging from 2.8%
(UK study of OCS use in patients 13–65 yr
old with GINA step 2 or greater
treatment) (77) to 93.5% (U.S. study of
OCS use for patients of all ages with
uncontrolled asthma) (78). Variations were
likely related to differences in inclusion
criteria, geography, and availability of
Ovid MEDLINE and
Ovid Embase
combined search:
3,387 records
Selected for
full-text evaluation:
387 records
Selected for data extraction
and analysis:
149 articles
Excluded:
1,890 records
Reasons for exclusion
•  Duplicate: 336
•  Clinical trial: 312
•  Review article: 246
•  <100 patients: 234
•  Case report: 206
•  Animal/in vitro study: 137
•  Not asthma/multiple indications: 128
•  ED/hospitalized patient: 69
•  No relevant outcomes: 37
•  Meta-analysis/pooled analysis: 33
•  Pregnancy: 32
•  Management/education: 30
•  Age <5 years: 24
•  Comment/editorial: 23
•  Guidelines: 16
•  Asthma phenotyping analysis: 13
•  Other*: 14
Excluded:
238 records
Reasons for exclusion
•  Published before 2010: 74
•  No relevant data: 59
•  Age <5 years: 38
•  <500 patients: 33
•  Mixed indications: 18
•  <100 patients: 4
•  ED/hospitalized patient: 3
•  Pooled analysis: 2
•  Other†: 7
Excluded:
10 records
Reasons for exclusion
•  Duplicate patient populations: 10
Initial screening
(title and abstract):
2,277 records
Excluded:
1,110 duplicates removed electronically
Included in the systematic
literature review:
139 studies
Figure 1. Flow diagram of the article screening and evaluation process. *“Other” included
asthma–chronic obstructive pulmonary disease overlap syndrome (n=5), letter (n=4), erratum (n=2),
not English language (n=2), and retracted publication (n=1). †“Other” included cost-effectiveness
modeling, letter, not patients with asthma, not English language, asthma phenotyping analysis,
controlled trial, and retracted publication (each n=1). ED=emergency department.
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OCS-sparing treatments. No clear geographic
or age-related variations in general OCS use
were observed in the identiﬁed studies
(Tables 3 and E7). OCS use was typically
reported for approximately 20–48% of
patients in the general asthma population
over a 1-year study period (Table 3) (79–83).
One study reported OCS use by 66% of
patients over a 2-year period (U.S. study of
adult patients) (49).
Similar incidences of general OCS use
(range 18.3–47.2%) were observed in four
of ﬁve studies involving patients receiving
GINA step 2 or greater treatment across all
age categories (Table 3) (4, 84–86). The
exception was a UK-based retrospective
cohort study (adolescent/adult patients) in
which general OCS use was reported by
5.7%, 6.4%, and 7.4% of patients in the year
before they initiated ICS, LABA, or
ICS/LABA treatment, respectively (77).
General OCS use in studies involving
patients with moderate or severe asthma was
generally greater than that reported in
studies involving a broader asthma
population, although considerable
interstudy variation existed (Table 3). OCS
use ranged from 33.2% to 65% in ﬁve
studies of patients with moderate-to-severe
or severe asthma (6- to 12-mo assessment
period) (87–91). A small cross-sectional
study conducted in Italy and France
reported general OCS use by 64.7% of
patients with severe asthma in the previous
year (88).
Clinical characteristics of patients
prescribed CS. Overall, OCS users tended to
be older than nonusers (Table E7) (30,
92–94). A U.S.-based prospective cohort
study reported that for patients with severe
asthma, long-term OCS use was more
common among adults than among
children/adolescents (22.4% and 9.9%,
respectively, had at least 3 mo of OCS use
in the previous year) (25). There was a
greater percentage of female patients
among OCS users in three U.S.-based
studies reporting on use for patients with
asthma overall, persistent asthma, and
moderate-to-severe asthma (Table E7)
(92–94). The percentage of patients
receiving long-term OCS was greatest in the
subgroups of patients who reported the
greatest number of exacerbations (42, 46,
58, 62, 95). Disease severity and relative
resistance to standard therapy (high-dosage
ICS, LABA, and other controllers) are
among the potential explanations for this
ﬁnding. In addition, studies suggested that
general and short-term OCS use was
greater among obese patients than among
nonobese patients. However, this may
reﬂect the relatively poorer asthma control
in this patient population (80, 88). A U.S.-
based study reported that compared with
nonusers or patients receiving short-term
OCS therapy, adult patients who had
uncontrolled asthma and were receiving
long-term OCS were more likely to have
received specialist asthma care (18.9% vs.
52.8%, respectively) and to have
experienced more asthma exacerbations
(rate: 0.3 vs. 1.6, respectively) (94). In all
studies that reported on disease severity, for
both long-term and short-term use, there
was a strong correlation between increasing
OCS use and increasing disease severity.
Clinical Burden of SCS
Comorbidities and complications associated
with OCS/SCS use for patients with asthma
were reported in 17 studies. Eleven of those
studies reported OCS use (60, 72, 82, 93, 94,
96–101) and six reported SCS use
(102–107).
Studies reported that the use of both
short- and long-term OCS was consistently
associated with a greater risk of acute and
chronic CS-related complications compared
with no OCS use. The risk of complications
increased with increasing exposure (Table
E8). A study that assessed the risk of any CS-
related AEs reported a 1.3-fold increase in
risk with long-term OCS use compared with
no OCS use (108).
Acute complications. Identiﬁed studies
reported acuteOCS-associated complications
that included infections and gastrointestinal
events (Table E8). In a U.S.-based matched
cohort study, approximately three times as
many OCS users (>30 d/yr) had pneumonia
(28.4%) and opportunistic infections (1.5%)
compared with non-OCS users (10.9% and
0.4%, respectively) (93). Four of ﬁve studies
that reported gastrointestinal complications
with OCS use found an increased risk
associated with long-term use versus no use
(odds ratio [OR], 1.035 [ulcers/bleeds] to
2.89 [gastroesophageal reﬂux]) (93, 94, 96,
97, 100).
Chronic complications. Identiﬁed
studies reported chronic OCS-associated
complications that included metabolic,
bone-related, and cardiovascular events
(Table E9). Most studies (U.S. and UK)
reported increased risks of comorbid
diabetes and obesity for patients with
severe asthma and greater/long-term
OCS/SCS use compared with patients
with milder disease and less/no OCS use
(93, 96, 100). However, one U.S.-based
retrospective cohort study of adults with
persistent asthma reported a similar
prevalence of diabetes between patients with
long- and short-term OCS use (94).
Bone- and muscle-related
complications. Four studies reported an
increased risk of bone- and muscle-related
complications with long-term OCS use
versus no use (Table E8) (93, 94, 96, 100).
For example, one study reported that current
OCS users with asthma (>4 prescriptions/
yr) had ORs of 1.44 and 1.21 for
osteoporosis and bone fracture, respectively,
compared with nonusers (100).
Cardiovascular complications. Identiﬁed
studies consistently reported an association
between long-term OCS use and increased
risk of cardiovascular complications,
hypertension, and hypercholesterolemia
compared with no use or short-term use
(Table E9) (60, 82, 93, 94, 96, 100). For
example, in a UK-based matched cohort
study of adults and adolescents, comorbid
hypertension was more common with long-
term OCS use among patients with severe
asthma (34%) than with less OCS use among
patients with mild-to-moderate asthma
(29%) or without asthma (25%) (96). In a
U.S.-based cross-sectional study of patients
with asthma, long-term OCS use was
signiﬁcantly associated with systemic
hypertension using univariate analysis. The
association was no longer signiﬁcant after
adjustment for demographic and asthma-
related variables and presence of obstructive
sleep apnea (60). Importantly, in a U.S.-
based retrospective cohort study, long-
term OCS use was also associated with
risk of coronary heart disease (hazard
ratio, 2.59) and heart failure (hazard ratio,
3.48) (82).
Psychiatric complications. Identiﬁed
studies reported mixed results for the
association between OCS use and
psychiatric complications (Table E9). A
UK-based matched cohort study found that
greater OCS use among patients with severe
asthma was associated with a signiﬁcant
increase in the prevalence of comorbid
psychiatric conditions compared with less
OCS use (38% and 31%, respectively, vs. 25%
for non–OCS use) (96). In a U.S.-based
retrospective study, adults with persistent
asthma reported an increased prevalence of
anxiety (16.2% vs. 10.6%), but not
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Table 3. General OCS and SCS Use for Patients with Asthma, Categorized by Disease Severity
Source Sample Size
OCS or SCS Use at
Follow-Up/Postindex, % (n/N)
OCS or SCS Use at
Baseline/Preindex, % (n/N)
Any degree of asthma severity
Afshar et al., 2017 (130) (U.S.) 14,012 (all individuals) OCS —
Asthma prevalence:
7.4%
8.8 (95% CI, 6.2–11.3)
Arellano et al., 2011 (79) (U.S.) 6–18 yr: 659,169 OCS —
6–11 yr: 348,991 6–18 yr: 25.2 (165,783/659,169)
6–11 yr: 27.6 (103,292/374,068)
Black et al., 2012 (80) (U.S.) 74,057 — OCS
31.2
(23,115/74,057)
Bjo¨rnsdo´ttir et al., 2014 (131)
(Iceland)
6,142 — OCS
12.7 (783/6,142)
Butler et al., 2016 (132) (U.S.) 123,868 OCS —
Jan 2005: 7.3%
Choi et al., 2017 (133) (South
Korea)
831,613 OCS —
40.61
Cooper et al., 2015 (134) (UK) 2,624 OCS —
12.0 (314/2,624)
Delate et al., 2017 (135) (U.S.) 2,360 SCS SCS
30.6 (723/2,360) 35.8 (845/2,360)
P, 0.001 vs. preintervention —
Farber et al., 2017 (81) (U.S.) 5–8 yr: 20,645 OCS —
9–12 yr: 14,716 Rx (2,015)
13–17 yr: 11,142 5–8 yr (N=20,645)
1: 31.9 (6,580)
2: 6.6 (1,371)
>3: 3.5 (720)
9–12 yr (N=14,716)
1: 28.2 (4,143)
2: 5.3 (781)
>3: 2.2 (317)
13–17 yr (N=11,142)
1: 30.1 (3,357)
2: 4.3 (484)
>3: 2.4 (269)
Iribarren et al., 2012 (82) (U.S.) 203,595 — OCS
20%
Laforest et al., 2015 (136)
(France)
UK: 38,637 SCS —
Non: 6,996
Low: 14,903
High: 16,738
Non/low/high ICS*
UK: 6.2%/22.5%/12.7%
France: 4,587 P,0.0001
Non: 1,176
Low: 1,358
High: 2,053
France: 21.9%/36.1%/30.5%
P,0.0001
Lee et al., 2014 (137) (South
Korea)
736 SCS —
71 (523/736)
Lin et al., 2016 (107) (Taiwan) 24,109 — SCS
3 mo: 8.0 (1,926/24,109)
12 mo: 22.3 (5,378/24,109)
Luskin et al., 2016 (49) (U.S.) 67,860 Any OCS use —
66.0 (44,764/67,860)
Walters et al., 2011 (101) (UK) 3,320 — OCS
Cases: 1,660 Cases: 57.4%
Control subjects: 1,660† Control subjects: 42.6%† P, 0.001
Windt and Glaeske, 2010 (138)
(Germany)
DMP: 317 OCS OCS
Not DMP (control): 317‡ DMP: 26.5 (84/317) DMP: 25.9 (82/317)
Not DMP (all): 20,566 Control: 24.3 (77/317)x Control: 20.5 (65/317)x P=0.002
Not DMP: 25.9 (5,320/20,566)
(Continued )
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Table 3. (Continued )
Source Sample Size
OCS or SCS Use at
Follow-Up/Postindex, % (n/N)
OCS or SCS Use at
Baseline/Preindex, % (n/N)
Wong et al., 2010 (83) (U.S.) 1,835 OCS OCS
48.2 (884/1,835) 48.1 (882/1,835)
GINA step 2 or greater treatment
Ali et al., 2015 (77) (UK) 51,103 — OCS
ICS: 46,928 Overall: 5.8 (2,976/51,103)
LABA: 714 By postindex Tx
ICS/LABA: 3,461 ICS: 5.7 (2,673/46,928)
LABA: 6.4 (46/714)
ICS/LABA: 7.4 (257/3,461)
Bengtson et al., 2017 (4) (U.S.) Escalation: 5,044jj
Unchanged: 21,967jj
OCS —
Unchangedjj
31.9 (7,002/21,967)
Escalationjj
Pre: 29.8 (1,501/5,044)
Post: 30.7 (1,548/5,044)
Corrao et al., 2016 (84) (Italy) 2,335 OCS —
18.3 (428/2,335)
Hagiwara et al., 2010
(139) (U.S.)
FP: 469 SCS —
FSC: 3,881 Matched¶:
FP: 32 (143/447)
FSC: 24 (106/447) P=0.006
Hagiwara et al., 2013
(140) (U.S.)
18,283 SCS —
FSC: 14,044 Matched**:
MF: 4,239 FSC: 18.1 (688/3,799)
MF: 20.5 (780/3,799) P,0.001
Hagiwara et al., 2014 (141)
(U.S.)
7,779 — SCS claims and procedures
FP: 2,010 FP: 69 (1,385/2,010)
FSC: 5,769 FSC: 73 (4,232/5,769) P,0.001
Laforest et al., 2014 (85)
(France)
919 — OCS
Overall: 46.4 (394/849)
Laforest et al., 2014 (86)
(France)
2,162 OCS OCS
ICS: 2008, % (n) 2007, % (n)
1,757 ICS (N=1,757) ICS (N=1,757)
ICS1LTRA: 1,826 0 units: 57.4 (1,009) 0: 52.8 (928)
1 unit: 22.1 (388) 1: 24.4 (428)
2 units: 10.6 (187) 2: 11.5 (202)
>3 units: 9.8 (173) >3: 11.3 (199)
ICS1LTRA (N=1,826) ICS1LTRA
0 units: 57.7 (1,053) (N=1,826)
1 unit: 22.1 (403) 0 units: 53.1 (970)
2 units: 10.7 (195) 1 unit: 24.3 (443)
>3 units: 9.6 (175) 2 units: 11.4 (209)
>3 units: 11.2 (204)
Moderate-to-severe or severe
asthma
Broder et al., 2011 (87) (U.S.) 2003: 302 OCS —
2004: 970 2007 cohort:
33.2 (459/1,382)††2005: 1,301
2006: 1,361
2007: 1,382
Bruno et al., 2014 (88)
(France/Italy)
102 OCS —
64.7 (66/102)
DiSantostefano and Davis,
2011 (142) (UK)
1,233 SCS SCS
1–6 mo: 11% 7–12 mo: 9%
7–12 mo: 10% 1–6 mo: 19%
Eisner et al., 2012 (89) (U.S.) 2,878 — OCS
51.2 (1,473/2,878)
Lafeuille et al., 2013 (90) (U.S.) 3,044 — OCS
49 (1,479/3,044)
(Continued )
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depression (13.0% vs. 12.3%), with longer
OCS use compared with short-term use (94).
A database study of patients in the
Netherlands with difﬁcult-to-treat asthma
reported an association between long-term
OCS use and anxiety or depression (OR,
1.38) (97).
Ocular complications. Long-term OCS
use was associated with an increased risk of
cataracts, regardless of whether the risk was
compared with short-term use or no exposure
(Table E9) (93, 94, 96, 100). The OR for risk
of cataracts in current versus nonusers of
OCS was reported as 1.26 in one U.S.-based
study (93). In a UK-based matched cohort
study, cataracts were more common with
long-term OCS use among patients with
severe asthma (9%) than among those with
less OCS use and mild-to-moderate asthma
(5%) or without asthma (4%) (96). No studies
reported an association between OCS use and
increased risk of glaucoma.
Other complications. Included studies
provided limited data regarding the effects
of OCS therapy on the risk of other
complications. Individual studies reported
associations between long-term OCS use
and asthma-related bronchiectasis (72),
chronic kidney disease (96), and sleep
disorders (96).
Healthcare Resource Use and
Economic Impact of SCS Use
The impact of OCS/SCS use on healthcare
resource use and costs for patients with
asthma was reported in 12 studies
(Tables E10 and E11). Across eight
studies that evaluated the economic
burden of OCS use for patients with
asthma, long-term OCS and SCS use was
consistently associated with increased
healthcare costs compared with no or
short-term use (34, 49, 92, 96, 103, 105,
106, 109). However, short-term use was
also associated with increased costs and
healthcare resource use compared with no
OCS use.
Healthcare costs were reported to
increase with greater OCS exposure. Data
from a UK database estimated that the mean
annual total costs of high, low, and no
OCS use were £2,603, £978, and £560,
respectively (96). Another UK-based
database analysis reported that nonasthma-
related medication costs were 58% greater
for patients receiving long-term OCS than
for nonusers (costs included prescriptions
Table 3. (Continued )
Source Sample Size
OCS or SCS Use at
Follow-Up/Postindex, % (n/N)
OCS or SCS Use at
Baseline/Preindex, % (n/N)
Lafeuille et al., 2012 (78) (U.S.) 644 — 93.5 (602/644)
(OCS)
Sposato et al., 2017 (143) (Italy) 340 OCS —
OMB Tx duration <12 mo: 13%
<12 mo: 39 12–<24 mo: 9%
12–<24 mo: 94 24–<60 mo: 6%
24–<60 mo: 171 .60 mo: 3%‡‡
.60 mo: 36 ‡‡P=0.044 vs. <12 mo
Sullivan et al., 2015 (91) (U.S.) 25,297 OCS OCS
HDICS: 11,445 HDICS: 34% HDICS: 35%
HICS: 6,926 HICS: 65% HICS: 53%
OMB: 856 OMB: 52% OMB: 63%
Sweeney et al., 2014 (144) (UK) 2,670 pts with new
ICS/LABA Rx and no
prior ICS Rx
— OCS
5 (132/2,670)
Turner et al., 2017 (145) (UK) 2,660 OCS —
FDC ICS/LABA: 6.5%
ICS1LABA:
8.8% P=0.084
Definition of abbreviations: CI = confidence interval; DMP=disease management program; FDC= fixed-dose combination; FP= fluticasone propionate;
FSC=FP/SAL fixed-dose combination inhaler; GINA=Global Initiative for Asthma; HDICS=high-dosage ICS; HICS=high-intensity corticosteroids;
ICS= inhaled corticosteroids; LABA= long-acting b2-agonists; LTRA= leukotriene receptor antagonists; MF=mometasone furoate; OCS=oral
corticosteroids; OMB=omalizumab; Rx=prescription; SABA= short-acting b2-agonists; SCS= systemic corticosteroids; Tx = treatment.
*Groups were defined according to the value of the ICS to total asthma medication ratio in 2008: R=0% (non-ICS users), 0%,R,50% (low ICS ratio
group), and R>50% (high ICS ratio group). The ratio constituted the proportion of prescribed units of ICS out of the overall number of respiratory
medication units prescribed during 2008.
†Patients with asthma and a diagnosis of depression during the study period (cases) were matched to patients with asthma without depression (control
subjects) according to the date of asthma diagnosis.
‡Occasional, intermittent, or continuous ICS/LABA use in baseline period.
xPatients in the DMP group were propensity matched with non-DMP control subjects based on a range of variables, including demographics, asthma
care/therapy, and comorbidities.
jjEscalation group: ICS or ICS-containing therapy dosage increase; a switch between ICS, LABA, or LTRA, or add-on of another controller within 12
months after the index date. Unchanged group: patients with >1 additional fill indicating continuation of index treatment regimen within 12 months after
the index date.
¶Patients receiving FSC who stepped down to FSC at a smaller dosage of FP or switched to FP only at the same dosage. Patients in the FSC group were
matched to those in the FP group through propensity score matching.
**Each patient in the FSC group was matched to one patient in the MF group through propensity score techniques.
††Based on OCS use in the top 10 medication patterns.
‡‡Pharmacist intervention to reduce SABA over-dispensing.
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for proton pump inhibitors and
bisphosphonates, treatments used to manage
OCS-related AEs) (34). Nonmedication
costs were 19% greater and total healthcare
expenditures were 43% greater (34).
A U.S. claims-based analysis of adult
patients with asthma receiving high-dosage
OCS therapy reported that annual total
healthcare costs were signiﬁcantly greater for
patients with OCS-related complications
($25,168) than for those without such
complications ($21,882); however, asthma-
related costs were comparable between the
groups ($4,213 and $3,952, respectively) (49).
This association between healthcare costs
and OCS exposure might reﬂect OCS use itself
or disease severity. Patients with more severe
asthma are likely to have had greater OCS
exposure because of the need for treatment to
control their symptoms. They are also likely to
have incurred additional healthcare costs
associated with increased clinic visits and
hospitalizations for exacerbations. Currently,
the literature does not appear to address
indirect costs, such as lost productivity,
associated with long-term OCS use. A link
between treatment-related AEs and increased
healthcare costs and resource use was
identiﬁed in ﬁve articles that assessed the
comorbidities and AEs associated with long-
term OCS use (94, 96, 103, 105, 106).
Furthermore, evaluation of data from the UK
general practice database found that relative to
patients with no OCS exposure, the additional
costs for nonasthma-related medication use
were notably greater for patients with greater
OCS exposure (£772) than for those with less
OCS exposure (£112) (96).
Discussion
This systematic literature review identiﬁed a
large body of evidence from observational
studies documenting real-world clinical
practice regarding the use of OCS/SCS
therapy for the general asthma population
and especially for patients with more severe
disease. Identiﬁed studies reported that
short- and long-term OCS/SCS therapy is
widely used to treat patients with asthma,
particularly those with severe disease.
Overall, OCS use was typically reported in
approximately half of patients in the general
asthma population over a 1-year period, and
short-term use was reported in up to 36% of
patients (35–38, 110). Guidelines
recommend OCS for short-term treatment
of serious exacerbations or as add-on
maintenance therapy for patients with
severe disease that is not controlled by
high-dosage maintenance treatment (5).
These recommendations restrict OCS use to
an estimated 10% of patients with severe
disease (111) and approximately 10% who
experience an exacerbation in any given
year (112). Thus, our ﬁndings indicate that
in many instances, .10% of patients are
receiving OCS treatment, suggesting that
OCS may be overused for asthma
management.
Long-term OCS use was consistently
infrequent across all age groups for patients
with nonsevere disease (,2%). However, up
to 60% of patients with severe or
uncontrolled asthma were reported to have
received long-term OCS therapy. The
extent of long-term OCS/SCS use has not
been reported in other analyses.
Furthermore, identiﬁed studies reported
that OCS are used as long-term therapy at
dosages up to 22 mg/d (67, 68), which is
greater than the prednisone-equivalent
dosage (<7.5 mg/d) recommended in
GINA guidelines as add-on therapy for
patients with asthma that is not controlled
by high-dosage therapy (GINA step 4
treatment) (5). These results suggest that
patients are repeatedly treated with OCS at
increasingly greater dosages, possibly
despite their lack of response to OCS
therapy or because of the nontargeted
action of OCS. This may be because OCS
are considered generally effective for all
patients with asthma and are frequently
prescribed in the absence of deﬁned disease
markers and objective response monitoring,
such as lung function.
Notably, the identiﬁed studies
predominantly reported on patients from
Europe and North America, and therefore
these ﬁndings may be biased toward
approaches in these regions. It is possible
that OCS are used more widely in low-
income countries than in high-income ones
because they are inexpensive. Indeed, until
2010, the World Health Organization
recommended OCS as an essential
medication to treat asthma (113). Moreover,
payer criteria for biologics may impact OCS
prescribing. For example, several reports
from the United Kingdom (where four or
more courses of OCS are required for
eligibility for biologics) indicate that more
than half of patients with severe asthma
were prescribed four or more courses of
OCS in 1 year. However, the percentages
are lower for countries where there are no
such requirements or fewer courses are
required. In Australia, the payer
requirement is two or more courses, and
exemptions are available for OCS toxicity.
Studies have found that OCS are not
equally effective for all patients and that
most patients with severe asthma are steroid
resistant to varying extents, by deﬁnition of
their general lack of response to ICS (24, 25).
Clinical characteristics of asthma, including
eosinophilic airway inﬂammation, have
been identiﬁed as being associated with
response to OCS (1). Genetic factors have
been identiﬁed that could also account for
some of this patient variability in OCS
response (24, 114–118). For example,
genetic polymorphisms in the
glucocorticoid-induced transcript gene
GLCCI1 have been reported to account for
6.6% of the overall variability in clinical
responses to ICS (117, 118). However,
responses to both ICS and OCS are likely to
be affected by several genetic variations,
some of which have yet to be identiﬁed
(24).
Identiﬁed studies reported that the use
of both short- and long-term OCS/SCS is
associated with an increased risk of acute
and chronic complications, and this risk
increases with greater exposure. The risk of
any steroid-related AE was found to be up to
3.6-fold greater with long-term OCS use
than with no use (103, 106, 108). Patients
will become aware of any acute
complications, if they occur, after treatment
initiation. These complications can often
have serious short-term consequences.
However, patients may be less aware of the
chronic complications associated with
OCS/SCS use. In contrast, OCS/SCS-
associated chronic conditions are often
anticipated and monitored by physicians.
Conversely, acute conditions, namely
infections and gastrointestinal events, are
frequently not considered by prescribers,
although many OCS users experience acute
complications, and relatively fewer studies
have reported on these types of AEs. For
example, pneumonia was the most
frequently identiﬁed comorbidity associated
with severe asthma in the Severe Asthma
Research Program cohort of U.S. and UK
patients with severe asthma (119). Even
patients with low OCS exposure were
reported to have an increased risk of
infection (103). These ﬁndings are
consistent with recent publications that
were not included in our review (2, 120).
One publication reported that AEs for
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patients with asthma receiving SCS began
at cumulative exposures of 1.0 to ,2.5 g
(vs. .0 to ,0.5 g reference), suggesting a
relationship between cumulative SCS
exposure and risk of AEs (2). Another
publication reported that the 15-year
cumulative incidence of type 2 diabetes was
9.5% for OCS/SCS users versus 5.6% for
nonusers (120). However, the risk of type 2
diabetes began with a cumulative exposure
of 0.5 to ,1 g, which is equivalent to four
lifetime OCS/SCS courses. This suggests
that the incidence of comorbid type 2
diabetes is not necessarily exclusively
inﬂuenced by the cumulative dosage of
OCS (2). However, cumulative OCS/SCS
exposure may not be an ideal measure
because of possible variations among
patients with regard to factors such as
disease duration and severity. It is
potentially an important metric for the
medical community to understand and
adopt in a clinical setting because it
provides a means of assessing long-term
exposure and associated adverse effects of
OCS/SCS use. As with the response to
OCS/SCS treatment, the risk of any patient
experiencing an AE is likely to be inﬂuenced
by underlying genetic factors, many of which
have yet to be identiﬁed (24, 121).
The burden of comorbidities associated
with both long-term and repeated short-
term OCS/SCS use adds to the asthma
burden, leading to increased risks of
hospitalizations and emergency department
visits, and corresponding increased
healthcare resource use.We found reports of
43% greater overall healthcare expenditures
for patients receiving long-term OCS
therapy compared with nonusers, and 58%
greater nonasthma-related costs (including
costs of treatments used to manage OCS-
related AEs) (108). Thus, although a
prescriber’s decision to use OCS/SCS
therapy instead of targeted treatments can
be inﬂuenced by the initial unit price,
incurred healthcare costs associated with
OCS/SCS use may bring the validity of this
choice into question. However, not all of
the increased costs for patients receiving
OCS are potentially directly attributable to
OCS-related AEs: the direct costs arising
from the management of severe asthma,
such as treatment and hospitalization costs,
are also likely to contribute to this increase.
In an analysis of patients with asthma who
were receiving intermittent or long-term
SCS matched with patients who were not,
42% greater overall costs were reported for
those who were receiving SCS (120). The
associated average annual costs for adverse
outcomes and asthma were £1,483 and
£403, respectively, for patients receiving
SCS, compared with £1,165 and £166,
respectively, for nonusers. The individual
contribution of OCS sparing to patients’
health-related quality of life is also difﬁcult
to elucidate. In future studies, the use of a
global approach that includes generic and
disease-related patient health-related
quality of life questionnaires could help
investigators assess the effects of OCS
reduction and distinguish between
improvements that result from reduced
OCS use and those that are attributable to
improved asthma control. It is also
difﬁcult to directly attribute the
occurrence of some common
comorbidities in the general population to
OCS use. For example, gastroesophageal
reﬂux disease is particularly common
among patients with asthma. This
condition is worsened by OCS use but can
be improved by greater asthma control
and increased patient activity (122).
Our review has several advantages over
similar publications. This review included a
search of both MEDLINE and Embase
databases. We also used a strong methodology,
with a study design that allowed the inclusion of
a wide range of ages (children, adolescents, and
adults), the full spectrum of disease, and the
prevalence of both short- and long-term use.
This resulted in the identiﬁcation and reporting
of results from 139 studies that included
populations with varying degrees of asthma
severity. Our ﬁndings are robust compared with
recent reviews that identiﬁed fewer publications
(,50 studies) and reported only on long-term
OCS use among adult patients with severe
asthma or AEs and their corresponding
economic burden (28, 123, 124).
The limitations of our review include
the fact that our search was conducted in
December 2017, and congress abstracts
were not included. Therefore, some
more recent studies may have been
omitted from our review. We also used
the deﬁnitions of long-term and short-
term use provided in the identiﬁed
literature, but interpretations varied
among the studies. Another potential
limitation is our inclusion of 13
studies that reported results of patient
surveys, as the data from such surveys
are considered to be weaker than those
obtained from cohort or database studies.
Furthermore, some studies from which
data were obtained were not designed to
directly identify AEs associated with
OCS/SCS use. Therefore, AEs may have been
underreported in those studies. In addition,
data on dose-dependent effects and the
frequency of OCS/SCS use associated with
AEs were not available for all studies and are
not summarized here. The information
provided on asthma severity varied among
the identiﬁed studies, which prevented us
from obtaining a more generalized synthesis
of the data by GINA treatment step.
Overall, a considerable amount of available
data was obtained from retrospective reports
from patients and physicians, and as such,
was subject to recall bias. These data suggest
that use remains a frequent component of
treatment for patients with asthma, primarily
related to the lack of control with other
medications. They also suggest that OCS/SCS
use is widespread and associated with
signiﬁcant adverse effects. Quantitation of
these data would be helpful, but this was
beyond the scope of this review. Future
longitudinal studies using objective
methods to collect data regarding the use of
OCS and its associated clinical burden are
needed.
Overall, this review demonstrates that
OCS and SCS, including long-term OCS,
continue to be commonly used and overused
for the management of asthma across the
disease spectrum and particularly for severe
asthma. This use is associated with both acute
and chronic complications. Importantly,
patients receiving repeated short-term, high
OCS dosages may incur a greater risk of AEs
than those receiving long-term, low dosages, as
the risk of AEs increases with the cumulative
OCS dosage. The introduction of biologics has
led to a reduction in OCS use in other disease
areas, but our review shows that a similar
change has not yet occurred for asthma (18).
This is because biologics have only recently
been approved for the treatment of severe
asthma. Omalizumab was the only add-on
biologic therapy available for the treatment of
severe asthma during the time periods
covered in many of the identiﬁed studies
(18). The recent approval of further
biologic treatments that reduce asthma
symptoms and exacerbation risks and
allow OCS tapering for OCS-dependent
patients has the potential to reduce future
OCS use for patients with asthma (10–14,
16, 17). n
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